Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SR 02

Next Previous
X
Search
Drug Profile

SR 02

Alternative Names: Allogeneic pancreatic endocrine cell clusters - Seraxis; SR-02

Latest Information Update: 19 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seraxis
  • Class Gene therapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 29 Oct 2024 Seraxis has a pending worldwide patent for methods for preparing and use of isolated synthetic replacement endocrine (SRE) cells for treating diabetes
  • 29 Oct 2024 Seraxis has patent protection for use of pancreatic cells for treating diabetes and methods of generating the same in USA, China and Japan
  • 29 Oct 2024 Seraxis has patent protection for use of stem cells and pancreatic cells for treatment of insulin-dependent diabetes in China, Europe, Australia, Japan, Canada, Spain and USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top